About the company
Panbela Therapeutics Inc is at the forefront of the biopharmaceutical industry, dedicated to developing innovative and disruptive therapeutics to address urgent unmet medical needs. With a focus on patients who require immediate intervention, the company is committed to bringing hope and improved outcomes to those suffering from debilitating diseases. One of Panbela's pipeline assets, ivospemin (SBP-101), holds significant promise as a breakthrough treatment. In clinical trials, ivospemin has demonstrated its ability to reset dysregulated biology, making it a potential game-changer in the field of cancer therapeutics. By targeting multiple pathways involved in the growth and metastasis of cancer cells, ivospemin offers a comprehensive approach that has the potential to enhance patient outcomes and revolutionize cancer treatment as we know it. Another promising asset in Panbela's pipeline is FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac. Eflornithine, a compound historically used to treat African sleeping sickness, has shown great potential in inhibiting tumor growth. By combining it with sulindac, an anti-inflammatory drug, FlynpoviTM has the ability to tackle both the dysregulated cell proliferation associated with cancer and the inflammatory responses that can aggravate the disease. This dual approach holds promise for patients suffering from various types of cancer, providing a much-needed option for targeted and effective treatment. Additionally, Panbela Therapeutics is exploring the potential of eflornithine (CPP-1X) as a standalone treatment. Eflornithine has shown promise in inhibiting the production of polyamines, essential molecules for cell growth and proliferation. By selectively targeting and depleting polyamines, eflornithine has the potential to disrupt dysregulated cellular processes in a wide range of diseases, including cancer and autoimmunity. This unique approach offers new possibilities for patients who have exhausted conventional treatment options, bringing new hope and potentially life-saving therapies. Panbela Therapeutics' commitment to developing disruptive therapeutics goes beyond the laboratory. The company is actively engaged in collaborations and partnerships with leading research institutions, medical centers, and pharmaceutical companies. Through these collaborations, Panbela aims to accelerate the development and commercialization of its pipeline assets, ensuring that groundbreaking treatments reach patients in need as quickly as possible. Driven by a patient-centric approach, Panbela Therapeutics Inc is dedicated to improving the lives of those facing urgent unmet medical needs. With a robust pipeline fueled by cutting-edge science and strategic collaborations, the company is poised to make a significant impact in the field of biopharmaceuticals. By continuing to innovate and develop disruptive therapeutics, Panbela Therapeutics is opening new doors for patients worldwide, offering a ray of hope and a chance for a better future.
Website: https://www.panbela.com
Data updated: May 4, 2026
